DaVita Inc. (NYSE:DVA) Shares Purchased by Summit Trail Advisors LLC

Summit Trail Advisors LLC boosted its stake in DaVita Inc. (NYSE:DVA) by 9.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,416 shares of the company’s stock after purchasing an additional 2,107 shares during the period. Summit Trail Advisors LLC’s holdings in DaVita were worth $3,801,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its holdings in DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock valued at $99,846,000 after purchasing an additional 92,014 shares in the last quarter. KBC Group NV grew its stake in shares of DaVita by 0.8% during the fourth quarter. KBC Group NV now owns 316,155 shares of the company’s stock valued at $47,281,000 after acquiring an additional 2,636 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of DaVita by 23.9% during the third quarter. BNP Paribas Financial Markets now owns 292,039 shares of the company’s stock valued at $47,874,000 after acquiring an additional 56,389 shares in the last quarter. Nordea Investment Management AB grew its stake in shares of DaVita by 4.9% during the fourth quarter. Nordea Investment Management AB now owns 264,535 shares of the company’s stock valued at $39,712,000 after acquiring an additional 12,339 shares in the last quarter. Finally, abrdn plc grew its stake in shares of DaVita by 1.2% during the third quarter. abrdn plc now owns 189,065 shares of the company’s stock valued at $30,719,000 after acquiring an additional 2,180 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Stock Performance

Shares of NYSE DVA opened at $173.63 on Tuesday. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. The firm’s 50-day moving average price is $160.79 and its two-hundred day moving average price is $156.75. DaVita Inc. has a 52-week low of $108.76 and a 52-week high of $179.60. The stock has a market capitalization of $14.24 billion, a P/E ratio of 18.73, a P/E/G ratio of 0.84 and a beta of 0.94.

Analysts Set New Price Targets

Separately, Barclays raised their target price on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $161.80.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.